


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

1. - 40. (canceled)

41. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and a compound of Formula I:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

X is O;

Y is CN;

Z is NR₈R₉, wherein R₈ and R₉ are independently H or C₁₋₄ alkyl;

R₅ is hydrogen or C₁₋₁₀ alkyl;

A is optionally substituted C₆₋₁₄ aryl; and

B is an optionally substituted indolo ring.


42. (previously presented) The pharmaceutical composition of claim 41, wherein A is optionally substituted phenyl.

43. (canceled)

44. (original) The pharmaceutical composition of claim 41, wherein X is O, Y is CN and Z is NH₂.

45. (original) The pharmaceutical composition of claim 41, wherein R₅ is hydrogen.

46. (previously presented) The pharmaceutical composition of claim 41, comprising a pharmaceutically acceptable excipient or carrier and a compound of Formula II:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R₃-R₄ are independently hydrogen, halo, haloalkyl, aryl, carbocyclic, C₁₋₁₀ alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, carbocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; R₁ and R₂ taken together with the atoms to which they are attached form a pyrrolo group, wherein said group is optionally substituted;

wherein the aryl portion of said arylalkyl, the aryl portion of said arylalkenyl and the aryl portion of said arylalkynyl are each independently C₆₋₁₄ aryl; and

said carbocyclic is C₃₋₈ cycloalkyl or C₃₋₈ cycloalkenyl.

47. (previously presented) The pharmaceutical composition of claim 46, wherein R₁ and R₂ are taken together to form a structure -CH=CH-N(R)-, wherein R is hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl.


48.- 49. (canceled)

50. (previously presented) The pharmaceutical composition of claim 46, wherein Z is NH₂.

51. (original) The pharmaceutical composition of claim 46, wherein R₅ is hydrogen.

52. (canceled)

53. (previously presented) The pharmaceutical composition of claim 46 comprising said compound or a pharmaceutically acceptable salt or prodrug thereof, wherein said optionally substituted C₆₋₁₄ aryl is



and

(a) R₁₀-R₁₄ are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, C₁₋₁₀ alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, carbocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; or

(b) R₁₀ and R₁₁, or R₁₁ and R₁₂, taken together with the atoms to which they are attached form a fused portion of said optionally substituted C₆₋₁₄ aryl, wherein said fused portion is optionally substituted.

54. (previously presented) The pharmaceutical composition of claim 53, wherein R₁ and R₂ are taken together to form a structure -CH=CH-N(R)-, wherein R is hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl.

55. - 59. (canceled)

60. (previously presented) The pharmaceutical composition of claim 54, wherein R₃, R₄ and R₅ are each hydrogen.

61. - 62. (canceled)

63. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and a compound selected from the group consisting of:

2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(2-bromo-4,5-dimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-8-methyl-4*H*-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3-nitrophenyl)-4*H*-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3-cyanophenyl)-4*H*-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-4*H*-indolo[4,5-b]pyran; and
9-Acetamide-2-amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-indolo[4,5-b]pyran.

64.-65. (canceled).

66. (original) The pharmaceutical composition of claim 41, wherein said excipient or carrier is selected from the group consisting of saccharides, starch pastes, gelatin, tragacanth, cellulose preparations, calcium phosphates and polyvinyl pyrrolidone.

67. (original) The pharmaceutical composition of claim 66, wherein said excipient or carrier is a saccharide selected from the group consisting of lactose, sucrose, manitol and sorbitol.

68. (original) The pharmaceutical composition of claim 41, wherein said excipient or carrier is a lipophilic solvent.

69. (original) The pharmaceutical composition of claim 68, wherein said lipophilic solvent is selected from the group consisting of fatty oils, fatty acid esters, polyethylene glycols and paraffin hydrocarbons.


70. (original) The pharmaceutical composition of claim 69, wherein said lipophilic solvent is selected from the group consisting of sesame oil, ethyl oleate, triglycerides, polyethylene glycol-400, cremophor and cyclodextrins.

71. (original) The pharmaceutical composition of claim 41, wherein said excipient or carrier is selected from the group consisting of vegetable oils, mineral oils, white petrolatum, branched chain fats, branched chain oils, animal fats and high molecular weight alcohol (greater than C₁₂).

72. (original) The pharmaceutical composition of claim 41, wherein said excipient or carrier is a saline solution.

73. - 74. (canceled)

75. (previously presented) A compound of Formula I:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

B is optionally substituted indolo;

X is O;

Y is CN;

Z is NR₈R₉, wherein R₈ and R₉ are independently H or C₁₋₄alkyl;

R₅ is hydrogen or C₁₋₁₀ alkyl; and

A is optionally substituted C₆₋₁₄ aryl.

76. (original) The compound of claim 75, wherein said compound is an optionally substituted 4H-indolo[4,5-b]pyran.

77. (original) The compound of claim 76, wherein A is optionally substituted phenyl.

78. (previously presented) A compound selected from the group consisting of:

2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-indolo[4,5-*b*]pyran;

2-Amino-3-cyano-4-(2-bromo-4,5-dimethoxyphenyl)-4*H*-indolo[4,5-*b*]pyran;

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-indolo[4,5-*b*]pyran;

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-8-methyl-4*H*-indolo[4,5-*b*]pyran;

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4*H*-indolo[4,5-*b*]pyran;

2-Amino-3-cyano-4-(3-nitrophenyl)-4*H*-indolo[4,5-*b*]pyran;

2-Amino-3-cyano-4-(3-cyanophenyl)-4*H*-indolo[4,5-*b*]pyran;

2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-4*H*-indolo[4,5-*b*]pyran; and

9-Acetamide-2-amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-indolo[4,5-*b*]pyran.

79. (canceled)

80. (currently amended) The pharmaceutical composition of claim 41, wherein said aryl is selected from the group consisting of phenyl, naphthyl, ~~penanthrenyl~~ phenanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylenyl and fluorenyl.

81. (currently amended) The compound of claim 75, wherein said aryl is selected from the group consisting of phenyl, naphthyl, ~~penanthrenyl~~ phenanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylenyl and fluorenyl.

82. - 93. (canceled)

94. (previously presented) The pharmaceutical composition of claim 41,
wherein said aryl is phenyl.

95. (previously presented) The compound of claim 75, wherein said aryl is
phenyl.